← Back to headlines
Regeneron stock drops after failed melanoma trial
Regeneron's stock has fallen 10% following the failure of its Phase 3 melanoma trial, raising questions about the company's future prospects.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
